Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients

By Zucman David   De Truchis P.   Peytavin Gilles   Descamps Diane   Duvivier C.   Tegna L.   Weiss Laurence   Delassus Jean L.   Benalycherif A.   Landman Roland  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 5, 2013-05 ,pp. : 407-410

Informa Healthcare

Access to resources Recommend Favorite

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

By Gisslén Magnus   Fuchs Dietmar   Hagberg Lars   Svennerholm Bo   Zetterberg Henrik  

Scandinavian Journal of Infectious Diseases, Vol. 44, Iss. 12, 2012-12 ,pp. : 997-1000

Informa Healthcare

Access to resources Recommend Favorite

A phase 1 clinical trial of sequential pralatrexate followed by a 48‐hour infusion of 5‐fluorouracil given every other week in adult patients with solid tumors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3862-3868

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

By Di Biagio Antonio  

Journal of Infection and Chemotherapy, Vol. 18, Iss. 4, 2012-08 ,pp. : 587-590

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite